Webinar: How AI-driven insights from RWD accelerate the diagnosis and treatment of undiagnosed patients: a case study
AI-driven insights & RWD in Rare Disease: Accelerate AATD Diagnosis and identify undiagnosed AATD patients earlie...
Volv Global generates insights that create new understanding of disease progression and the patient journey, closing the gap between disease onset and effective treatment.
We help transform lives by giving pharmaceutical innovators powerful insights into difficult-to-diagnose diseases so they can develop effective tools and treatments.
For the person living with the disease, this results in quicker diagnosis, earlier support from clinicians and the possibility of innovative treatments – whether that’s a new drug or an existing one used in a novel way
Volv Global works directly with the pharmaceutical companies developing the next generation of therapies. We cannot support individual patients as we do not have connections with physicians or healthcare providers at the local or regional level.
Recognising that patients living with difficult-to-diagnose diseases may also arrive on our pages, we attempt, below, to offer a few lists of resources for possible approach. This list is necessarily incomplete, and we will continue to update it as we learn more.
Please note: Volv Global has no official affiliation with any of the organisations mentioned on this page.
Volv Global started in rare and difficult-to-diagnose diseases
Rare diseases manifest in less than one person among thousands. Doctors have less experience with them, and developers of therapies and payers have less patients to draw understanding from … leaving patients in a healthcare limbo.
Depending on definitions of “rare,” over 300 million people – or 3.5-5.9% of the world population – suffer from 6,000-10,000 rare diseases.
Please note: Volv Global has no official affiliation with these organisations.
Upon diagnosis, patients need a deep and thorough understanding of the disease and the likelihood of how the disease will progress.
Patients also require support to understand treatment options, as well as availability in their geographical location. In certain cases, awareness of available clinical research trials may be useful.
Rare Rebels: A Storytelling Movement to Support the Rare Disease Community
Please note: Volv Global has no official affiliation with these organisations.
Go deeper
AI-driven insights & RWD in Rare Disease: Accelerate AATD Diagnosis and identify undiagnosed AATD patients earlie...
Volv Global presented 2 posters at ATS 2025 showing work to assess how machine learning models can identify patients ...
A prediction model to identify symptomatic patients of different races and ethnicities with risk of Alpha-1 Antitryps...
Discover how Volv Global’s inTrigue AI helps identify rare disease patients earlier, improves diagnosis accuracy, and...
Case Study: Detecting signs of Fabry and Pompe disease in UK clinical data